Abstract
Objective: To examine the relationships between physical growth and medications prescribed for symptoms of attention-deficit hyperactivity disorder in children with HIV. Methods: Analysis of data from children with perinatally acquired HIV (N = 2251; age 3-19 years), with and without prescriptions for stimulant and nonstimulant medications used to treat attention-deficit hyperactivity disorder, in a long-term observational study. Height and weight measurements were transformed to z scores and compared across medication groups. Changes in z scores during a 2-year interval were compared using multiple linear regression models adjusting for selected covariates. Results: Participants with (n = 215) and without (n = 2036) prescriptions were shorter than expected based on US age and gender norms (p < .001). Children without prescriptions weighed less at baseline than children in the general population (p < .001) but gained height and weight at a faster rate (p < .001). Children prescribed stimulants were similar to population norms in baseline weight; their height and weight growth velocities were comparable with the general population and children without prescriptions (for weight, p = .511 and .100, respectively). Children prescribed nonstimulants had the lowest baseline height but were similar to population norms in baseline weight. Their height and weight growth velocities were comparable with the general population but significantly slower than children without prescriptions (p = .01 and .02, respectively). Conclusion: The use of stimulants to treat symptoms of attention-deficit hyperactivity disorder does not significantly exacerbate the potential for growth delay in children with HIV and may afford opportunities for interventions that promote physical growth. Prospective studies are needed to confirm these findings.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 403-412 |
| Number of pages | 10 |
| Journal | Journal of Developmental and Behavioral Pediatrics |
| Volume | 30 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 1 2009 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Psychiatry and Mental health
- Developmental and Educational Psychology
- Medicine(all)
- Pediatrics, Perinatology, and Child Health
Cite this
}
Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV. / Sirois, Patricia A.; Montepiedra, Grace; Kapetanovic, Suad; Williams, Paige L.; Pearson, Deborah A.; Malee, Kathleen; Garvie, Patricia A.; Kammerer, Betsy L.; Nichols, Sharon L.; Nozyce, Molly L.; Mintz, Mark; Mitchell, Wendy G.; Oleske, James.
In: Journal of Developmental and Behavioral Pediatrics, Vol. 30, No. 5, 01.10.2009, p. 403-412.Research output: Contribution to journal › Article
TY - JOUR
T1 - Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV
AU - Sirois, Patricia A.
AU - Montepiedra, Grace
AU - Kapetanovic, Suad
AU - Williams, Paige L.
AU - Pearson, Deborah A.
AU - Malee, Kathleen
AU - Garvie, Patricia A.
AU - Kammerer, Betsy L.
AU - Nichols, Sharon L.
AU - Nozyce, Molly L.
AU - Mintz, Mark
AU - Mitchell, Wendy G.
AU - Oleske, James
PY - 2009/10/1
Y1 - 2009/10/1
N2 - Objective: To examine the relationships between physical growth and medications prescribed for symptoms of attention-deficit hyperactivity disorder in children with HIV. Methods: Analysis of data from children with perinatally acquired HIV (N = 2251; age 3-19 years), with and without prescriptions for stimulant and nonstimulant medications used to treat attention-deficit hyperactivity disorder, in a long-term observational study. Height and weight measurements were transformed to z scores and compared across medication groups. Changes in z scores during a 2-year interval were compared using multiple linear regression models adjusting for selected covariates. Results: Participants with (n = 215) and without (n = 2036) prescriptions were shorter than expected based on US age and gender norms (p < .001). Children without prescriptions weighed less at baseline than children in the general population (p < .001) but gained height and weight at a faster rate (p < .001). Children prescribed stimulants were similar to population norms in baseline weight; their height and weight growth velocities were comparable with the general population and children without prescriptions (for weight, p = .511 and .100, respectively). Children prescribed nonstimulants had the lowest baseline height but were similar to population norms in baseline weight. Their height and weight growth velocities were comparable with the general population but significantly slower than children without prescriptions (p = .01 and .02, respectively). Conclusion: The use of stimulants to treat symptoms of attention-deficit hyperactivity disorder does not significantly exacerbate the potential for growth delay in children with HIV and may afford opportunities for interventions that promote physical growth. Prospective studies are needed to confirm these findings.
AB - Objective: To examine the relationships between physical growth and medications prescribed for symptoms of attention-deficit hyperactivity disorder in children with HIV. Methods: Analysis of data from children with perinatally acquired HIV (N = 2251; age 3-19 years), with and without prescriptions for stimulant and nonstimulant medications used to treat attention-deficit hyperactivity disorder, in a long-term observational study. Height and weight measurements were transformed to z scores and compared across medication groups. Changes in z scores during a 2-year interval were compared using multiple linear regression models adjusting for selected covariates. Results: Participants with (n = 215) and without (n = 2036) prescriptions were shorter than expected based on US age and gender norms (p < .001). Children without prescriptions weighed less at baseline than children in the general population (p < .001) but gained height and weight at a faster rate (p < .001). Children prescribed stimulants were similar to population norms in baseline weight; their height and weight growth velocities were comparable with the general population and children without prescriptions (for weight, p = .511 and .100, respectively). Children prescribed nonstimulants had the lowest baseline height but were similar to population norms in baseline weight. Their height and weight growth velocities were comparable with the general population but significantly slower than children without prescriptions (p = .01 and .02, respectively). Conclusion: The use of stimulants to treat symptoms of attention-deficit hyperactivity disorder does not significantly exacerbate the potential for growth delay in children with HIV and may afford opportunities for interventions that promote physical growth. Prospective studies are needed to confirm these findings.
UR - http://www.scopus.com/inward/record.url?scp=74049163645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74049163645&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/DBP.0b013e3181ba0cf6
DO - https://doi.org/10.1097/DBP.0b013e3181ba0cf6
M3 - Article
C2 - 19827220
VL - 30
SP - 403
EP - 412
JO - Journal of Developmental and Behavioral Pediatrics
JF - Journal of Developmental and Behavioral Pediatrics
SN - 0196-206X
IS - 5
ER -